UWCCC Molecular Tumor Board Registry

Recruiting

• Conditions: Hematologic Neoplasms; Solid Neoplasm
• Interventions: Other: PMMTB (Precision Medicine Molecular Tumor Board)

• Registration Number: NCT03023202
• Lead Sponsor: University of Wisconsin, Madison

Brief Summary

This study seeks to evaluate the clinical utility of the Precision Medicine Molecular Tumor Board, and to track patient outcomes.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-03-30
• Study First Submitted: 2017-01-13
• Study First Submitted QC: 2017-01-13
• Study First Posted: 2017-01-18
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-16
• Last Update Posted: 2025-04-22
• Primary Completion: 2027-03
• Study Completion: 2027-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 10000

Inclusion Criteria

• Clinically suspected or histologically confirmed solid or hematological malignancy
• Undergoing genetic testing of tumor
• Ability to understand written informed consent document
• Willingness to sign written informed consent document

Exclusion Criteria

• Pediatric patients (age<18 years) will be excluded due to a lack of expertise on the molecular tumor committee

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
PMMTB	PMMTB (Precision Medicine Molecular Tumor Board)	This study of the PMMTB will include all patients \>= 18 with clinically suspected or histologically confirmed solid or hematological malignancy who will undergo genetic testing of their tumor. All standard of care functions will be performed by standard procedures.

Primary Outcome Measures

Name	Time	Method
Benefit from PMMTB recommended treatment	Up to 5 years	Whether patients benefit from PMMTB recommended treatment
Frequency of acceptance of molecular tumor board recommendations	Up to 5 years	How often the molecular tumor board's recommendations are accepted

Secondary Outcome Measures

Name	Time	Method
Correlation of mutations with protein overexpression	Up to 5 years	Correlate mutations identified in tumor tissue with protein overexpression
Correlations of mutations with spheroid culture investigations	Up to 5 years	Correlate mutations identified in tumor tissue with spheroid culture investigations
Correlations of mutations with circulating tumor DNA	Up to 5 years	Correlate mutations identified in tumor tissue with circulating tumor DNA

Trial Locations

Locations (1)

University of Wisconsin Carbone Cancer Center; 🇺🇸 Madison, Wisconsin, United States